LAVA Therapeutics NV
NASDAQ:LVTX
LAVA Therapeutics NV
NASDAQ:LVTX
Price:
3.03 USD
-2.26%
Market Closed
Updated:
May 4, 2024
LAVA Therapeutics NV
Operating Income
|
LAVA Therapeutics NV
Operating Income Peer Comparison
Comparables:
PHARM
QURE
ARGX
MRUS
N
NAMS
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Operating Income
-$43.3m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Operating Income
-$21.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-13%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Operating Income
-$282.9m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-24%
|
|
|
argenx SE
XBRU:ARGX
|
Operating Income
-$420.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Operating Income
-$156.5m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Operating Income
-€3.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is LAVA Therapeutics NV's Operating Income?
Operating Income
-43.3m
USD
-43.3m
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Operating Income amounts to -43.3m USD.
What is LAVA Therapeutics NV's Operating Income growth rate?
Operating Income CAGR 3Y
-43%
-43%
Over the last year, the Operating Income growth was -24%. The average annual Operating Income growth rates for LAVA Therapeutics NV have been -43% over the past three years .
You don't have any saved screeners yet
